USANA Health Sciences (USNA) Expected to Announce Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is projected to issue its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $225.9590 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 11:00 AM ET.

USANA Health Sciences Price Performance

NYSE:USNA opened at $20.95 on Friday. The stock has a market cap of $382.97 million, a P/E ratio of 23.81, a PEG ratio of 0.89 and a beta of 0.67. USANA Health Sciences has a 1-year low of $18.48 and a 1-year high of $38.32. The firm has a 50-day moving average of $20.68 and a two-hundred day moving average of $23.79.

Institutional Trading of USANA Health Sciences

A number of large investors have recently modified their holdings of the business. National Bank of Canada FI lifted its stake in shares of USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in USANA Health Sciences by 382.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after purchasing an additional 1,327 shares in the last quarter. Parallel Advisors LLC boosted its holdings in USANA Health Sciences by 1,354.3% in the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after buying an additional 3,589 shares during the period. Finally, Quantbot Technologies LP boosted its position in shares of USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after acquiring an additional 646 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on USNA. Zacks Research cut USANA Health Sciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.